Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 312, Issue 4, 2017, Pages H781-H790

  Kimura, Takayuki ^a   Tse, Kevin ^a   McArdle, Sara ^a   Gerhardt, Teresa ^a   Miller, Jacqueline ^a   Mikulski, Zbigniew ^a   Sidney, John ^a   Sette, Alessandro ^a   Wolf, Dennis ^a   Ley, Klaus ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Apolipoprotein B 100; Atherosclerosis; CCR5; FoxP3; IL 10; Immunization; MHC class II

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B P101 PEPTIDE; APOLIPOPROTEIN B P102 PEPTIDE; APOLIPOPROTEIN B P103 PEPTIDE; CHEMOKINE RECEPTOR CCR5; FREUND ADJUVANT; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOB PROTEIN, MOUSE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; IC50; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TRIACYLGLYCEROL BLOOD LEVEL; VACCINATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; GENE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; METABOLISM; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENES, MHC CLASS II; IMMUNOGLOBULIN G; INTERLEUKIN-10; LIPOPROTEINS, LDL; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; VACCINATION;

EID: 85017007569     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00798.2016     Document Type: Article

References (53)

1. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12: 178-180, 2006. doi:10.1038/nm1343.
2. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114: 427-437, 2004. doi:10.1172/JCI200420479.
3. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Hörkkö S, Miller YI, Woelkers DA, Corr M, Witztum JL. The role of natural antibodies in atherogenesis. J Lipid Res 46: 1353-1363, 2005. doi:10.1194/jlr.R500005-JLR200.
4. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 23: 454-460, 2003. doi:10.1161/01.ATV.0000059419.11002.6E.
5. Butcher MJ, Filipowicz AR, Waseem TC, McGary CM, Crow KJ, Magilnick N, Boldin M, Lundberg PS, Galkina EV. Atherosclerosisdriven treg plasticity results in formation of a dysfunctional subset of plastic IFNγ+ Th1/Tregs. Circ Res 119: 1190-1203, 2016. doi:10.1161/CIRCRESAHA.116.309764.
6. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A. Phosphorylcholinetargeting immunization reduces atherosclerosis. J Am Coll Cardiol 50: 540-546, 2007. doi:10.1016/j.jacc.2006.11.054.
7. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109: 745-753, 2002. doi:10.1172/JCI7272.
8. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 9: 10-17, 2003.
9. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240, 1994. doi:10.1126/science.7520605.
10. Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, Frangogiannis NG. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol 176: 2177-2187, 2010. doi:10.2353/ajpath.2010.090759.
11. Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, Skaflen MD, Cutchins A, Lee DJ, Glover DK, Kelly KA, Galkina EV, Ley K, Witztum JL, Tsimikas S, Bender TP, McNamara CA. B-cell aortic homing and atheroprotection depend on Id3. Circ Res 110: e1-e12, 2012. doi:10.1161/CIRCRESAHA.111.256438.
12. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond) 101: 523-531, 2001. doi:10.1042/cs1010523.
13. Freigang S, Hörkkö S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehydemodified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18: 1972-1982, 1998. doi:10.1161/01.ATV.18.12.1972.
14. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MGA. A CD4+ T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389: 737-742, 1997. doi:10.1038/39614.
15. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 12: 204-212, 2011. doi:10.1038/ni.2001.
16. Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, Perez N, Barateau V, Nilsson J, Tedgui A, Mallat Z. Regulatory T cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32: 605-612, 2012. doi:10.1161/ATVBAHA.111.242800.
17. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 123: 1083-1091, 2011. doi:10.1161/CIRCULATIONAHA.110.973222.
18. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 207: 1081-1093, 2010. doi:10.1084/jem.20092243.
19. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30: 531-564, 2012. doi:10.1146/annurev.immunol.25.022106.141623.
20. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107-2112, 2003. doi:10.1161/01.CIR.0000092891.55157.A7.
21. Kimura T, Tse K, Sette A, Ley K. Vaccination to modulate atherosclerosis. Autoimmunity 48: 152-160, 2015. doi:10.3109/08916934.2014.1003641.
22. Krzyszton CP, Sparkman NL, Grant RW, Buchanan JB, Broussard SR, Woods J, Johnson RW. Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation. Am J Physiol Regul Integr Comp Physiol 295: R1109-R1114, 2008. doi:10.1152/ajpregu.90302.2008.
23. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993. doi:10.1016/0092-8674(93)80068-P.
24. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariéty J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104: 197-202, 2001. doi:10.1161/01.CIR.104.2.197.
25. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120: 417-426, 2009. doi:10.1161/CIRCULATIONAHA.109.868158.
26. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31: 1506-1516, 2011. doi:10.1161/ATVBAHA.110.221127.
27. Li J, Ley K. Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol 35: 40-49, 2015. doi:10.1161/ATVBAHA.114.303227.
28. Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, Weber C, Ley K. CCR5+T-bet+FoxP3+ effector CD4 T cells drive atherosclerosis. Circ Res 118: 1540-1552, 2016. doi:10.1161/CIRCRESAHA.116.308648.
29. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 123: 27-36, 2013. doi:10.1172/JCI63108.
30. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 108: 1232-1237, 2003. doi:10.1161/01.CIR.0000089083.61317.A1.
31. Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 208: 1279-1289, 2011. doi:10.1084/jem.20110308.
32. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10: 1178-1184, 2009. doi:10.1038/ni.1791.
33. Osborne BA, Smith SW, Liu ZG, McLaughlin KA, Grimm L, Schwartz LM. Identification of genes induced during apoptosis in T lymphocytes. Immunol Rev 142: 301-320, 1994. doi:10.1111/j.1600-065X.1994.tb00894.x.
34. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92: 821-825, 1995. doi:10.1073/pnas.92.3.821.
35. Pils MC, Pisano F, Fasnacht N, Heinrich JM, Groebe L, Schippers A, Rozell B, Jack RS, Müller W. Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model. Eur J Immunol 40: 443-448, 2010. doi:10.1002/eji.200939592.
36. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 90: 1064-1071, 2002. doi:10.1161/01.RES.0000018941.10726.FA.
37. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res 52: 1829-1836, 2011. doi:10.1194/jlr.M015776.
38. Sage AP, Nus M, Baker LL, Finigan AJ, Masters LM, Mallat Z. Regulatory B cell-specific interleukin-10 is dispensable for atherosclerosis development in mice. Arterioscler Thromb Vasc Biol 35: 1770-1773, 2015. doi:10.1161/ATVBAHA.115.305568.
39. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133: 775-787, 2008. doi:10.1016/j.cell.2008.05.009.
40. Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110: 2047-2052, 2004. doi:10.1161/01.CIR.0000143162.56057.B5.
41. Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 50: 2313-2318, 2007. doi:10.1016/j.jacc.2007.07.081.
42. Sidney J, Southwood S, Moore C, Oseroff C, Pinilla C, Grey HM, Sette A. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr Protoc Immunol 18: 18.3, 2013. doi:10.1002/0471142735.im1803s100
43. Sjögren P, Fredrikson GN, Samnegard A, Ericsson CG, Ohrvik J, Fisher RM, Nilsson J, Hamsten A. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 29: 2218-2226, 2008. doi:10.1093/eurheartj/ehn336.
44. Tse K, Gonen A, Sidney J, Ouyang H, Witztum JL, Sette A, Tse H, Ley K. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100. Front Immunol 4: 493, 2013. doi:10.3389/fimmu.2013.00493.
45. Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. Int Immunol 25: 615-622, 2013. doi:10.1093/intimm/dxt043.
46. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48: 425-433, 2007. doi:10.1194/jlr.M600361-JLR200.
47. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21: 95-100, 2001. doi:10.1161/01.ATV.21.1.95.
48. van Wanrooij EJ, Happé H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25: 2642-2647, 2005. doi:10.1161/01.ATV.0000192018.90021.c0.
49. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E_/_ mice. J Iinterferon Cytokine Res 22: 661-670, 2002. doi:10.1089/10799900260100141.
50. Wigren M, Kolbus D, Dunér P, Ljungcrantz I, Söderberg I, Björkbacka H, Fredrikson GN, Nilsson J. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 269: 546-556, 2011. doi:10.1111/j.1365-2796.2010.02311.x.
51. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223: 284-299, 2008. doi:10.1111/j.1600-065X.2008.00646.x.
52. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 107: 4240-4243, 2006. doi:10.1182/blood-2005-09-3922.
53. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102: 2919-2922, 2000. doi:10.1161/01.CIR.102.24.2919.